肿瘤
腫瘤
종류
TUMOR
2009年
7期
663-667
,共5页
周凌%虞佩%王建丰%宋科瑛%江爱芳%徐红%李克
週凌%虞珮%王建豐%宋科瑛%江愛芳%徐紅%李剋
주릉%우패%왕건봉%송과영%강애방%서홍%리극
乳腺肿瘤%干细胞%乙醛脱氢酶1%免疫组织化学
乳腺腫瘤%榦細胞%乙醛脫氫酶1%免疫組織化學
유선종류%간세포%을철탈경매1%면역조직화학
Breast neoplasms%Stem cells%Aldehyde dehydrogenase 1%Immunohistochemistry
目的:探讨肿瘤干细胞标志物乙醛脱氢酶1(aldehyde dehydrogenase 1,ALDH1)在乳腺癌中的表达及其临床意义.方法:采用免疫组织化学染色法检测92例乳腺癌患者肿瘤组织中ALDH1蛋白的表达,并结合临床病理特征进行相关性分析和无病生存期分析.结果:ALDH1蛋白在乳腺癌组织中的阳性表达与孕激素受体(progesterone receptor, PR)和cerb-B2有关(P<0.05),与患者年龄、肿瘤大小、临床分期以及是否有淋巴结转移无关(P>0.05).ALDH1阳性患者2年无病生存率显著低于ALDH1阴性患者(P<0.05),接受CEF方案化疗和内分泌治疗的ALDH1阳性患者2年无病生存率显著低于ALDH1阴性患者(P<0.05).结论:ALDH1蛋白表达阳性的乳腺癌患者其无病生存率降低与耐药有关,ALDH1可作为乳腺癌预后判断的指标.
目的:探討腫瘤榦細胞標誌物乙醛脫氫酶1(aldehyde dehydrogenase 1,ALDH1)在乳腺癌中的錶達及其臨床意義.方法:採用免疫組織化學染色法檢測92例乳腺癌患者腫瘤組織中ALDH1蛋白的錶達,併結閤臨床病理特徵進行相關性分析和無病生存期分析.結果:ALDH1蛋白在乳腺癌組織中的暘性錶達與孕激素受體(progesterone receptor, PR)和cerb-B2有關(P<0.05),與患者年齡、腫瘤大小、臨床分期以及是否有淋巴結轉移無關(P>0.05).ALDH1暘性患者2年無病生存率顯著低于ALDH1陰性患者(P<0.05),接受CEF方案化療和內分泌治療的ALDH1暘性患者2年無病生存率顯著低于ALDH1陰性患者(P<0.05).結論:ALDH1蛋白錶達暘性的乳腺癌患者其無病生存率降低與耐藥有關,ALDH1可作為乳腺癌預後判斷的指標.
목적:탐토종류간세포표지물을철탈경매1(aldehyde dehydrogenase 1,ALDH1)재유선암중적표체급기림상의의.방법:채용면역조직화학염색법검측92례유선암환자종류조직중ALDH1단백적표체,병결합림상병리특정진행상관성분석화무병생존기분석.결과:ALDH1단백재유선암조직중적양성표체여잉격소수체(progesterone receptor, PR)화cerb-B2유관(P<0.05),여환자년령、종류대소、림상분기이급시부유림파결전이무관(P>0.05).ALDH1양성환자2년무병생존솔현저저우ALDH1음성환자(P<0.05),접수CEF방안화료화내분비치료적ALDH1양성환자2년무병생존솔현저저우ALDH1음성환자(P<0.05).결론:ALDH1단백표체양성적유선암환자기무병생존솔강저여내약유관,ALDH1가작위유선암예후판단적지표.
Objective:The purpose of this study is to investigate the expression of tumor stem cell marker aldehyde dehydrogE-nase 1 (ALDH1) in breast cancer and its clinical significance. Methods:The expression of ALDH1 protein was examined by immunohistochemical staining in 92 breast cancer tissues. The correlation analysis and diseasE-free survival analysis of patients was evaluated based on the clinical follow-up data. Results:Expression of ALDH1 protein had a significant correlation with progesterone receptor (PR) and cerb-B2 (P<0.05), but had no significant correlation with age, tumor size, clinical staging, and lymph node metastasis (P>0.05). The 2-year diseasE-free survival rate of AlDH1-positive patients was lower than that of ALDH1-negative patients (P<0.05). ALDH1-positive patients, who received CEF regimen chemotherapy and hormone therapy, had lower 2-year diseasE-free survival rate than that of ALDH1-negative patients (P<0.05). Conclusion:The decreased diseasE-free survival rate of ALDH1-positive patients is related with drug resistance. ALDH1 could be used as an independent factor for predicting the prognosis of breast cancer.